cart

0.00
HPLC testedCOA every batchEU shippingSEPA · secure paymentResearch Use Only
PEPTIQA BIOTECHTesamorelin10 mgPurity 8% · RUO

Excellent

Rating 4.8 / 5 — early quality score

Peptiqa Reviews

Early quality score — buyers can leave a review after verified purchase.

Tesamorelin

10 mg8% purityLot #TESAMO-2026-001

SKU of selected dimension: PEP-TESA-10MG

Tesamorelin is a synthetic peptide composed of 44 amino acids and represents a modified analog of growth hormone-releasing hormone (GHRH). A trans-3-hexenoic acid moiety has been added to its N-terminal region, enhancing its stability and prolonging its biological half-life compared with endogenous GHRH. Marketed as Egrifta® and Egrifta SV®, it remains the only FDA-approved GHRH analog specifically authorized for the treatment of excess visceral abdominal fat in adults affected by HIV-associated lipodystrophy. Through selective stimulation of growth hormone secretion from the pituitary gland, Tesamorelin primarily reduces deep visceral adipose tissue while helping preserve both subcutaneous fat stores and lean body mass. Large randomized controlled trials have consistently demonstrated reductions in abdominal trunk fat and waist circumference, along with improvements in patient body image, without many of the adverse effects commonly associated with direct HGH administration.
€201.30incl. VAT
In Stock (40)

Volume pricing

QuantityUnit priceSavings
1 vial201.30
3 vials (−7%)186.66−7%
5 vials (−12%)176.90−12%
Purchase & earn 165 points!

Ratings & reviews

Log in to rate this product after your order arrives. login

Certificate of Analysis

Lab Verified
View certificate before purchase — transparency guaranteed
Research Profile

Tesamorelinscientific profile

Content is for educational and research purposes. Research Use Only.

  • Tesamorelin is a synthetic peptide composed of 44 amino acids and represents a modified analog of growth hormone-releasing hormone (GHRH). A trans-3-hexenoic acid moiety has been added to its N-terminal region, enhancing its stability and prolonging its biological half-life compared with endogenous GHRH. Marketed as Egrifta® and Egrifta SV®, it remains the only FDA-approved GHRH analog specifically authorized for the treatment of excess visceral abdominal fat in adults affected by HIV-associated lipodystrophy.
  • Through selective stimulation of growth hormone secretion from the pituitary gland, Tesamorelin primarily reduces deep visceral adipose tissue while helping preserve both subcutaneous fat stores and lean body mass. Large randomized controlled trials have consistently demonstrated reductions in abdominal trunk fat and waist circumference, along with improvements in patient body image, without many of the adverse effects commonly associated with direct HGH administration.

More from GH peptidi

This site uses cookies

Accept